Abstract: The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).
| # | Name | Date |
|---|---|---|
| 1 | 202517067567-STATEMENT OF UNDERTAKING (FORM 3) [15-07-2025(online)].pdf | 2025-07-15 |
| 2 | 202517067567-Sequence Listing in PDF [15-07-2025(online)].pdf | 2025-07-15 |
| 3 | 202517067567-REQUEST FOR EXAMINATION (FORM-18) [15-07-2025(online)].pdf | 2025-07-15 |
| 4 | 202517067567-POWER OF AUTHORITY [15-07-2025(online)].pdf | 2025-07-15 |
| 5 | 202517067567-FORM 18 [15-07-2025(online)].pdf | 2025-07-15 |
| 6 | 202517067567-FORM 1 [15-07-2025(online)].pdf | 2025-07-15 |
| 7 | 202517067567-DECLARATION OF INVENTORSHIP (FORM 5) [15-07-2025(online)].pdf | 2025-07-15 |
| 8 | 202517067567-COMPLETE SPECIFICATION [15-07-2025(online)].pdf | 2025-07-15 |